Upcoming contract

Quote






























Forest and Cardio would probably be Bystolic, a beta blocker for hypertension and maybe Daliresp for severe COPD. That would be two of my guesses. Any more info on hiring process and timelines?????
 






Anonymous said:
I heard there is a new contract on the way after the most recent Amylin contract. Anyone know anything about it????
Click to expand...

Yes--most position filled, but check into them--legit opportunity. Preferred applicants have diabetes sales experience and relationships with primary care and endos in the territory. Best route--network to the Amylin rep in the territory with a personal reference (doc or other rep). They can submit you to a specific person that is supposed to get you an interview. Some good folks have slipped through the cracks, I'v heard, but this is what is supposed to be the process.

Hope it works out for you!
 






The contract and jobs were just announced last week..so how can most of the positions be already filled? I understand they are just getting started with Forest. Back to the question,
which products?"
 












Anonymous said:
The products to be promoted are Bystolic, Viibryd, and Namenda.
Click to expand...

You are correct. Poster #7 is referring to Amylin project...300 reps, 30 DMs. DMs hired in early March, reps hired in early April. Forest looking to pick up the pace on some newer products (Bystolic and Viibryd) along with Namenda to offset Lexapro patent loss later this year. They have two NDAs coming in 2012: one for COPD and one for IBS. They have several newer products...while not novel or first to class (by a long-shot), they are good bread and butter drugs that could be sold to fund more in the future...doesn't seem like a bad situation actually. I was suspect having heard lots of negative things about Forest but some quick research was pretty encouraging...just check out their site: frx.com
 






Anonymous said:
You are correct. Poster #7 is referring to Amylin project...300 reps, 30 DMs. DMs hired in early March, reps hired in early April. Forest looking to pick up the pace on some newer products (Bystolic and Viibryd) along with Namenda to offset Lexapro patent loss later this year. They have two NDAs coming in 2012: one for COPD and one for IBS. They have several newer products...while not novel or first to class (by a long-shot), they are good bread and butter drugs that could be sold to fund more in the future...doesn't seem like a bad situation actually. I was suspect having heard lots of negative things about Forest but some quick research was pretty encouraging...just check out their site: frx.com
Click to expand...

So, are the rep positions for this new contract posted yet? I heard Forest was going to creat some specialty positions. I agree, this doesn't sound bad, as contract positions go.
 












Rep positions have not been posted yet. Managers are having phone screening interviews this week and then will be flown for a face-to-face interviews the 2nd and 3rd weeks of February. Rep territory alignments have not been completed at this point. Continue to check the InVentiv website for territory postings. Should not be too much longer. Looks like a nice opportunity. Good luck to everyone!!
 












I talked recently to a recruiter at inventiv about this job. no pharma xp needed, just 2+ years of B2B. He referred to it as "entry level pharma"

it is Forest, but not certain on products. Why would they consider cardio sales entry level? maybe to just pay the reps less?
 






Top Bottom
Back
Quote